Content of Guidelines·Consensus·Commentary in our journal

        Published in last 1 year |  In last 2 years |  In last 3 years |  All
    Please wait a minute...
    For Selected: Toggle Thumbnails
    Expert Consensus on the Treatment of Pulmonary Tuberculosis Complicated with Chronic Hepatitis B Virus Infection
    National Clinical Research Center for Infectious Diseases Jiangxi Branch, Jiangxi Provincial Key Laboratory of Tuberculosis
    Chinese General Practice    2025, 28 (24): 2961-2967.   DOI: 10.12114/j.issn.1007-9572.2025.0121
    Abstract299)   HTML16)    PDF(pc) (1185KB)(119)       Save

    China is not only a high-burden country for tuberculosis (TB) but also bears the largest global burden of hepatitis B. The dual prevalence of TB and hepatitis B poses significant challenges, as co-infected patients face higher risks of treatment failure and relapse. A key clinical challenge lies in ensuring the effective implementation of anti-tuberculosis regimens while minimizing the incidence of liver injury and avoiding treatment interruptions caused by hepatic complications. Due to limited clinical research data in this area in China, comprehensive diagnostic and treatment guidelines for pulmonary TB complicated by chronic hepatitis B virus (HBV) infection have yet to be established. Based on this, and referencing relevant domestic and international guidelines and consensus documents, the National Clinical Research Center for Infectious Diseases Jiangxi Branch, Jiangxi Provincial Key Laboratory of Tuberculosis organized a panel of experts from various fields including tuberculosis, infectious diseases, hepatology, and pathology to conduct intensive discussions and develop 11 expert consensus recommendations. This consensus aims to provide guidance for standardized diagnosis and treatment as well as scientific management of tuberculosis patients co-infected with HBV.

    Table and Figures | Reference | Related Articles | Metrics
    Research on Blood Pressure Control and Its Determinants Among Hypertensive Patients Under Standardized Management in China: Status, Challenges, and Future Directions
    HE Jinyu, ZHULIDUZI Jiesisibieke, ZHANG Ning, LIU Min, LIANG Wannian
    Chinese General Practice    2025, 28 (24): 2968-2971.   DOI: 10.12114/j.issn.1007-9572.2024.0672
    Abstract379)   HTML26)    PDF(pc) (1176KB)(194)       Save

    Hypertension is a prevalent chronic condition with a sizable patient population and suboptimal blood pressure control rates, resulting in a substantial economic burden on individuals and society. Strengthening health management strategies for hypertensive patients is a crucial intervention to improve blood pressure control. Although standardized hypertension management has been widely implemented in primary care settings, existing studies indicate that blood pressure control rates in China remain unsatisfactory. This paper examines research did in China on the effectiveness of blood pressure control and the factors influencing it among hypertensive patients receiving standardized management. Several limitations in the current body of research are identified, including a paucity of high-quality studies, narrow research scope in terms of influencing factors, inconsistent selection of blood pressure metrics, varied approaches to evaluating long-term blood pressure management, and non-alignment of target blood pressure definitions with international guidelines. The paper proposes future research recommendations, such as standardizing blood pressure control criteria, expanding the study of patients under standardized management, broadening research perspectives to explore the impact of multilevel determinants on blood pressure control, and leveraging big data and artificial intelligence technologies to advance precision management for hypertensive patients.

    Reference | Related Articles | Metrics